C
ALNY icon

Certuity’s Alnylam Pharmaceuticals ALNY Stock Holding History

Certuity’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-654
Closed -$217K – 677
2026
Q1 		$217K Buy
+654
New +$223K 0.01% 578
2025
Q4 		– Sell
-468
Closed -$213K – 589
2025
Q3 		$213K Buy
+468
New +$191K 0.01% 511

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Certuity's ALNY Position: Q2 2026 in Review

Certuity sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 654 shares — an estimated $217K sold.

Certuity first reported a position in ALNY in Q3 2025 and held it in 2 quarters. The position peaked at $217K in Q1 2026. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Certuity reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Certuity sold 654 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $217K.
  • Certuity first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Certuity's Alnylam Pharmaceuticals position peaked at $217K in Q1 2026.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Certuity's 13F filing for Q2 2026, filed 28 Jul 2026.